Cost-utility analysis of edaravone dexborneol versus human urinary kallidinogenase for the treatment of acute ischemic stroke
Objective:To analyze the cost-utility of edaravone dexborneol versus human urinary kallidinogenase in patients with acute ischemic stroke.Methods:From China's healthcare system perspective,based on the individual patient data of clinical trial,the baseline patient characteristics were adjusted by matching-adjusted indirect comparison method to indirectly compare clinical efficacy indicators.A decision tree and Markov model were constructed for lifetime simulation,and the cost-utility analysis was conducted to compare the economics of the two treatments.One-way sensitivity and probabilistic sensitivity analyses were simultaneously performed to examine the robustness of the results.Results:Compared with human urinary kallidinogenase,edaravone dexborneol gained an additional 0.332 0 QALYs with an additional cost of 539.34 yuan,yielding an incremental cost-effectiveness ratio of 1 624.44 yuan per QALY,lower than 1fold of per capita GDP of China in 2022.Conclusion:Compared with human urinary kallidinogenase,edaravone dexborneol is an economic treatment for patients with acute ischemic stroke.
NETL
NSTL
万方数据
维普
